Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Fibroblastic reticular cells mitigate acute GvHD via MHCII-dependent maintenance of regulatory T cells
Haroon Shaikh, … , Jochen Huehn, Andreas Beilhack
Haroon Shaikh, … , Jochen Huehn, Andreas Beilhack
Published October 13, 2022
Citation Information: JCI Insight. 2022;7(22):e154250. https://doi.org/10.1172/jci.insight.154250.
View: Text | PDF
Research Article Hematology Transplantation

Fibroblastic reticular cells mitigate acute GvHD via MHCII-dependent maintenance of regulatory T cells

  • Text
  • PDF
Abstract

Acute graft versus host disease (aGvHD) is a life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT) inflicted by alloreactive T cells primed in secondary lymphoid organs (SLOs) and subsequent damage to aGvHD target tissues. In recent years, Treg transfer and/or expansion has emerged as a promising therapy to modulate aGvHD. However, cellular niches essential for fostering Tregs to prevent aGvHD have not been explored. Here, we tested whether and to what extent MHC class II (MHCII) expressed on Ccl19+ fibroblastic reticular cells (FRCs) shape the donor CD4+ T cell response during aGvHD. Animals lacking MHCII expression on Ccl19-Cre–expressing FRCs (MHCIIΔCcl19) showed aberrant CD4+ T cell activation in the effector phase, resulting in exacerbated aGvHD that was associated with significantly reduced expansion of Foxp3+ Tregs and invariant NK T (iNKT) cells. Skewed Treg maintenance in MHCIIΔCcl19 mice resulted in loss of protection from aGvHD provided by adoptively transferred donor Tregs. In contrast, although FRCs upregulated costimulatory surface receptors, and although they degraded and processed exogenous antigens after myeloablative irradiation, FRCs were dispensable to activate alloreactive CD4+ T cells in 2 mouse models of aGvHD. In summary, these data reveal an immunoprotective, MHCII-mediated function of FRC niches in secondary lymphoid organs (SLOs) after allo-HCT and highlight a framework of cellular and molecular interactions that regulate CD4+ T cell alloimmunity.

Authors

Haroon Shaikh, Joern Pezoldt, Zeinab Mokhtari, Juan Gamboa Vargas, Duc-Dung Le, Josefina Peña Mosca, Estibaliz Arellano Viera, Michael A.G. Kern, Caroline Graf, Niklas Beyersdorf, Manfred B. Lutz, Angela Riedel, Maike Büttner-Herold, Alma Zernecke, Hermann Einsele, Antoine-Emmanuel Saliba, Burkhard Ludewig, Jochen Huehn, Andreas Beilhack

×

Figure 6

MHCII on FRCs maintains functional CD4+FoxP3+ Tregs in the effector phase of aGvHD.

Options: View larger image (or click on image) Download as PowerPoint
MHCII on FRCs maintains functional CD4+FoxP3+ Tregs in the effector phas...
(A) MHCII-competent B6.H2-Ab1fl, MHCII-deficient B6.MHCIIΔ, and B6.MHCIIVav1Δ Cdh5Δ (lacking MHCII expression on all hematopoietic and endothelial cells) recipients were myeloablatively irradiated with 9 Gy and i.v. transplanted with 1 × 106 BALB/c.Nur77-GFP Tregs and 5 × 106 BALB/c WT TCD-BM. (B) Expression of Nur77-GFP as normalized MFI on donor CD3ε+CD4+H-2Kd Tregs on day 3 of allo-HCT in LNs. (C) LNs from B6.H2-Ab1fl, B6.MHCIIΔ, and B6.MHCIIVav1Δ Cdh5Δ were enzymatically digested and magnetically depleted of CD45+ cells, and 2 × 104 cells were cocultured with 8 × 104 BO-97.10 T hybridoma cells expressing an OVA-specific TCR along with titrated amounts of the OVA peptide 323–339. After 24 hours, supernatant was collected and analyzed for IL-2 production by ELISA. Data pooled from 2 experiments, with 1 data point representing 1 mouse. Two-way ANOVA with Tukey test was used; data are shown as mean± SD. *P < 0.05 and ****P < 0.0001. (D) Survival of myeloablatively irradiated (9 Gy) B6.H2-Ab1fl and B6.MHCIIΔCcl19 mice, transplanted with 5 × 106 TCD BM and 6 × 105 CD4+ T cells with/without 3 × 105 Tregs mice. Data are illustrated on Kaplan-Meier curve. (E) Experimental strategy: B6.CD11c.DOG recipients were myeloablatively irradiated with 9 Gy and i.v. transplanted with 5 × 106 splenocytes and 5 × 106 BM cells from B6.RagΔ.OTII.L2G85.CD45.1 and B6.WT mouse, respectively. At day +14 of syn-HCT, mice were euthanized and CD4+ T cells were enriched from the spleen and LNs. Subsequently 1 × 107 enriched CD4+ T cells were transplanted into B6.WT and B6.iFABP-tOVA mice. (F) Frequency of Ki67+ Tcons and Tregs at day +6 of adoptive transfer of OT-II CD4+ T cells in B6.WT and B6.iFABP-tOVA mice in spleen. Data pooled from 2 experiments, with 1 data point representing 1 mouse. Unpaired nonparametric Mann-Whitney U test was used; data are shown as mean± SD. **P < 0.01.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts